NEFL and frontotemporal dementia: The current information about blood biomarkers in FTD indicates that NfL is the main one and is useful in three approaches: the differentiation of bv-FTD from psychiatric disorders, as mentioned above, the prognosis of the onset of clinical disease in asymptomatic mutation carriers, and the monitoring of disease progression [26,27].